Procurement in 21st century in the chemical, pharmaceutical and healthcare industry by Makowski, T. (Thorsten) & Clauß, M. (Michael)
Procurement in 21st century in the chemical, pharmaceutical and healthcare
industry
© 2011 Institute of Business Administration123Journal of Business Chemistry 2011, 8 (3)
* PPV AG, Jägerstraße 67, 10117 Berlin,makowskiconsulting@online.de
** Pfarrer-Wachsmann-Straße 4, 17489 Greifswald,michael_clauss@gmx.net
ThorstenMakowski* andMichael Clauß**
Practitioner’s Section
Procurement in 21st century in the chemical,
pharmaceutical and healthcare industry
context of further globalization, profound
crises and technological development?
Where are future potentials?
What are Best-Practices in procurement?
Which trends shape procurement in future?
Together with renowned cooperation
partners we conducted this - regarding sample
size, scope and global focus biggest - global
procurement study. Important trends and targets
for procurement have been analyzed in order to
give recommendations for actions at top
management level.
The study is a cooperation of the international
chamber of commerce (ICC Germany), the most
1. Introduction
The financial crisis has clearly shown the
importance of procurement for many companies
success. Also the increasing globalization has
dramatically changed the importance and more
specific the challenges procurement is facing in
this rapidly changingworld.Unexploited potentials
are not only substantial, but also critical for the
competitive advantage and profitability of a
company.Against this backdropwewanted to give
answers on current relevant trends and questions
for procurement, such as: Has Procurement the
right setup within the context of further
globalization, profound crises and technological
development?
Has Procurement the right setup within the
Most companies in the Chemical, Pharmaceutical and Healthcare industry have a
procurement performance below average, which in turn means a disadvantage
compared to other industries. These companies are not able to realize their existing
cost reduction potentials in procurement.Additional short termpotentialswill not
be fully exploited, for example these due to the financial crisis.
A large fractionof companies fromthis industryhasneither a relevant procurement
strategynor a procurement controlling. It is easy to see, that companies neglecting
these basic elements have no chance to achieve a high procurement performance
and optimize potentials.
One specific problem is that the industry lacks of sufficient qualified procurement
personnel. At the same time important positions in procurement departments,
especially in strategic procurement,were vacant.
In general procurement in the Chemical, Pharmaceutical andHealthcare industry
has a strong operational focus.Highest prioritized topics are analysis of prices and
offers, calculation andplanning of demands andmanagement of supply shortages.
In comparison to other industries each of these topics has relevance above-average.
The major topics in strategic procurement are evaluation of suppliers, tendering
and qualification of suppliers as well as searching for new suppliers. Especially
tendering seems tobemore relevant for companies in theChemical,Pharmaceutical
andHealthcare industry than for companies in other industries.But still companies
in the Chemical, Pharmaceutical andHealthcare industry donot fully benefit from
maximum cost reduction effect from tendering.
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Company Performance =
These valuations are cardinal calibrated too.
This company valuation was done once based on
an apriori valuation of possible answers. After that
this process was done iterative: Based on the
answers of the good/bad performing companies
the valuation of the answerswas redone. Formost
answers thismeant a change of themagnitude of
the valuation. Only for a few answers even the
algebraic sign changed.
Valuation Revaluation
Subsequently the company valuation was
redone based on the new valuations.
Company Performance Revaluation
Company Performance
This iterative process was redone two times.
After this full iterative process all questions were
analyzed itself.We defined ameasurement for the
actual relevance for the overall performance of
eachquestionbymeasuring thedifferencebetween
the answers of goodperforming (first quartile) and
bad performing (last quartile) companies. This
differencewasmeasuredby a difference coefficient
which is between +100% and -100%.
+100% would mean that all good companies
chose the best (ticked) answers and all the bad
companies chose theworst (ticked) answers.Analog,
0% would mean that there is no difference at all
betweenhowgoodandbadperforming companies
answer this question.
Another objective of the study design was to
create an applicable cross-industry framework for
procurement and to set a proper basis for further
research and development activities in the field of
procurement. For that it was important to have a
broad base of questions and participants. It is
important to us that this procurement framework
is basedmainly onquantitativedata. In the following
passages the results of this framework based on
the study results for the Chemical,Pharmaceutical
and Healthcare industry are presented.
3.Methodology
3.1 Sourcing Market
The trend towards global sourcingwill continue
to increase for companies in Chemical,
Pharmaceutical andHealthcare industry.The current
important German Chambers of Commerce
abroad around the world, the Federation of
German Wholesale and Foreign Trade, the
Austrian Association of Material Supply,
Procurement and Logistics and the Lorange
Institute of Business, Zurich.
2.Methodology
Based on a questionnaire with 187 questions
procurement in the 21st century is analyzed based
on different topics regarding:
1. Impact of the financial crisis
2. Procurement strategy
3. Processes and organization
4. Procurement controlling
5. Supplier management
6. Benchmarking
More than 5,000 top executives from renowned
companies and various industriesworldwidewere
addressed and invited to participate in the study.
We received answers from800 companies from62
countries. Companies from the Chemical,
Pharmaceutical and Healthcare industry are
representing 13% of the participants in the study.
NorthAmerica,Asia and Europe are represented
in a similar extend.Also companies fromAustralia,
SouthAmerica andAfrica did participate.The study
examines all different business sectors.
All relevant decision levels havebeen considered
(procurement management and executive board
level).Therefore important operational and strategic
questions can be analyzed from a complementary
point of view. The data was collected from
September 2009 till January 2010.
For each of the 187 questions we conducted an
a priori valuation for all possible answers created
by experts.
(i:numberofquestion (1-187), j:numberof chosen
answer (1-number of possible answers))
Answer Valuation
The valuations are cardinal calibrated: A
valuationof zero stands for “averageperformance”,
a negative valuation stands for below average
performance and a positive valuation for above
average performance. The higher the valuation,
the higher is the performance.
Each participant gets evaluated as a company
by the average evaluation of his answers
(I: Total number of questions answered)
i i
j j
∑
i
Valuation i
j
i i
j j
I
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European companies assume that their
customers are typically not willing to pay a
surcharge for sustainable products.
North America
For North American companies sustainability
is less important than globally.
North American companies do not expect a
big increase in the usage of sustainable raw
materials. 
They are not willing to pay a surcharge for
sustainability but their customers are willing
to do it.
Asia
In Asia sustainability will gain more
importance than globally.
Asian companies consider sustainability more
as a competitive advantage than companies
from other regions.
Asian companies have the highest willingness
to pay a surcharge for sustainability
compared to companies from other regions,
although they assume that their customers
are not willing to pay this surcharge. This is
attributed to a more long term strategic
thinking.
3.4 Possible contribution to earnings from
procurement 
According to a self-assessment of purchasing
managers, there is on average a general cross-
industry cost reduction potential in procurement
of around 10%. With procurement costs being on
average around half of companies revenue, this
really is a lot. 
The financial crisis added another short-term
4% procurement cost reduction potential. In fact
companies were only able to realize sobering 1%
point of this additional saving potential within the
crisis. An unrealized potential of 3% points still
remains – see figure 1. For Companies in the
Chemical, Pharmaceutical and Healthcare industry
these numbers are different: they had higher
potentials. Out of these they realized 1.7%
procurement cost reduction and let 3.8%
unexploited.
In many industries procurement achieved first
major successes to play a role as value-adding player
over the past two decades. Due to a lower
procurement cost share on total cost in the
Chemical, Pharmaceutical, Healthcare industry and
sourcing markets in this sector will change more
than for many other industries. The traditionally
strong sourcing markets North America and Western
Europe are becoming less important, partially up
to one third. China remains the fastest growing
sourcing region for the Chemical, Pharmaceutical
and Healthcare industry.
3.2 Actions taken in times of crisis like the financial
crisis
A crisis is a good chance for procurement due
to declining procurement prices. For this reason
procurement should focus during a crisis on a
maximum short term exploitation of these
potentials. For companies in the Chemical,
Pharmaceutical and Healthcare industry it is often
difficult to achieve additional short term potentials
in procurement. In our evaluation only 28% of the
companies use a professional tendering
management to exploit the additional short term
potentials due to the financial crisis. 
Procurement in the analyzed companies of the
Chemical, Pharmaceutical and Healthcare industry
did not focus on exploiting potentials, they did just
the opposite: More than 60% of the analyzed
Chemical, Pharmaceutical and Healthcare
companies did a temporary reduction of working
hours, which is significantly more than in other
industries. These resources are missing for important
tasks. 
In this industry procurement is often seen as a
part of the supply chain with a strong focus on
supply reliability: if demand declines, resources
should also be reduced. 
3.3 Sustainability
Sustainability is as much as for other industries
an important challenge. There are no significant
differences between companies from the Chemical,
Pharmaceutical and Healthcare industry compared
to the other industries. Two thirds of all evaluated
companies state that there will be an increase of
sustainable materials but only half of the companies
are willing to pay a surcharge. The analysis reveals
some regional differences about sustainability: 
Europe
Importance of sustainability for European
companies is a little below average.
The usage of sustainable raw materials is
slightly below average for European
companies as well as the perceived
opportunity to create competitive advantages
from sustainability.
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4. Strategy
In our study we examined what separates
companies.
When analyzing best practices we sorted all of
these in three categories: Strategy, Organization
(including topics like Controlling, Reporting Line,
Personnel, and Incentives) and Processes. One
interesting question was which of these three areas
defines mostly the current procurement
performance status of companies. Is it company’s
Strategy defined by chief officers? Is it hands-on
Processes? Or is it Organization and Controlling?
Throughout the analysis we found out: it is Strategy!
The question whether you have a procurement
strategy is the most important question of all to
anticipate total procurement performance. As we
found out, this question has a very high difference
coefficient of 85%, which is very close to a perfect
100%.
When we look at this a little deeper, we found
out that having a procurement strategy comes in
three steps: (1) You define a strategy, (2) You
communicate it and (3) You act according to your
strategy.
Good performing companies pretty much always
have a procurement strategy and act according to
the typical focus on supply stability in process driven
industries this procurement transformation process
is in this industry neglected. As Figure 1 indicates
there is a huge potential to create value through
cost reduction in times of crisis and volatility.
3.5 Procurement performance ranking 
In our study we examined what separates
companies with the best procurement performance
worldwide from those which are only average. Is
there a relation between procurement performance
and the industry a company comes from?
It is a fair first guess to assume, that a very good
procurement performance can be found in those
sectors where procurement accounts for a high
percentage of the total costs. The success of a
company in these sectors is closely aligned with
the performance of their procurement function. 
The following figure 2 shows the average
performance by each industry according to our
performance index, as described in section 2. 
After our analysis the best performing sectors
according to our ranking are Retail and Consumer
goods. Based on our procurement performance
index the Chemical, Pharmaceutical and Healthcare
industry is ranked only on #9 out of 12 – see figure 2.
Figure 1 Additional potential and realization due to the finanical crisis 
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within the company. For most companies the
internal standing of procurement is lower than its
influence to the company’s total performance. On
average within all industries 44% of the companies
say, that procurements impact is very high. But only
22% of the companies indicate that procurement
has a very high internal standing. 
When we look at companies from Chemical,
Pharmaceutical and Healthcare industry this is even
worse: Because of its lower cost fraction in this
industry only 33% say that procurement has a very
high impact. This is slightly lower than the 44%
average. But only 6% of the companies from the
Chemical, Pharmaceutical and Healthcare industry
state that procurement has a very high standing. 
As mentioned before the gap between
procurements impact and standing is even higher
in pharmaceutical and healthcare industry. This is
something we found out in general: the worser
company`s procurement performs, the larger is the
gap between impact and standing of procurement.
5. Organization
5.1 Reporting line
Another important level for the procurement
of a company is its procurement organization model.
As Figure 3 shows is an organization of procurement
under the chief operations officer is the most
it. In contrast bad performing companies do not
even have procurement strategy at all (or rather no
strategy). 
Within all industries, on average a little more
than half of the companies say that they have a
procurement strategy. Furthermore 80% of the
companies who say that they have a strategy act
according to that strategy. 
Do companies in Chemical, Pharmaceutical and
Healthcare industry have a procurement strategy
and act according to it? Only 30% of companies in
the Chemical, Pharmaceutical and Healthcare
industry proclaim to have a procurement strategy,
which is bad compared to all other industries where
almost 60% of the companies have a procurement
strategy. 
We found out that after having a procurement
strategy, connecting this procurement strategy to
the company’s overall strategy is the second most
important attribute of your procurement strategy
for the procurement performance. More than 60%
of the companies within all industries do connect
their procurement strategy to the overall strategy.
For companies from Pharmaceutical and Healthcare
industry this is only little lower: a good half of these
companies do this.
Another very important strategic topic is the
standing of procurement within the organization.
On average there is a structural (perception) gap
between the impact of procurement and its power
Figure 2 Average procurement performance by industry
very poor poor good very good
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common in the Chemical, Pharmaceutical and
Healthcare industry with 63%. A chief operations
officer is focused mostly on (maximal) supply
reliability. Typically he does not define minimal
procurement costs as his major goal neither he gets
measured by it. 
So this constellation of the procurement function
reporting to the chief operations officer inevitably
creates a danger to lead to procurement
performance disadvantages– see figure 3.
To further examine the organizational topic we
asked the question, which board member should
ideally be responsible for the procurement function.
Compared to other industries procurement
reporting line to the chief operating officer (COO)
is more common – see figure 4.
It is remarkable that in the Chemical,
Pharmaceutical, Healthcare industry the vast
majority (79%) of the Chief Procurement Officers
(CPO) answered that they should not report to the
COO but to either the Chief Executive Officer (CEO)
or Chief Financial Officer (CFO) – see figure 4.
Figure 3 Organizational structure and performance for Chemical, Pharma, Healthcare
Where is procurement lined in your company? Performance by organisational structure
Chemical, Pharma, Healthcare
CFO
CEO
COO
very
poor poor
very
goodgood
13%
25%
63%
CEO = Chief Executive Officer, CFO = Chief Financial Officer, COO = Chief Operating Officer
Figure 4 Comparison as-is organizational model and to-be organizational model for Chemical, Pharma, Healthcare and
other industries
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and vacant positions in strategic procurement.
Particularly alarming is that procurement managers
are not successful, to communicate the issues about
lacking resources and capabilities to the top
management.
Almost half the companies in the Chemical,
Pharmaceutical, Healthcare industry answered they
have too few procurement personnel. 33% of the
participants from the Chemical, Pharmaceutical,
Healthcare industry answered that their
procurement employee's skills are not sufficient.
Other industries have only a fraction half as big as
that (17%) who say that the skills of their employees
are not sufficient – see figure 5.
A good 60% of procurement personnel in
Chemical, Pharmaceutical, Healthcare companies
have an academic degree, which is nearly 5% more
compared to other industries. However, in this case
it is no advantage according to the average
procurement performance in this industry. 
Rather, the highly qualified academic personnel
are not able to implement their knowledge in the
daily business. In general, the study shows that an
optimal procurement department needs “the right
mix” of theoretical and practical thinking personnel.
This creates a very special situation for
procurement in this industry compared to other
sectors. University graduates, many times with a
background in operations often logistics, production
(planning) or chemistry and not in procurement
form a situation in which procurement is perceived
as a poorly unimportant function with (not
appropriate) skilled employees who themselves
perceive their work in procurement as a periphery
5.2 Procurement controlling 
In the strategy part we found out that the most
important aspect of your procurement strategy is
whether a company has one. So what is the major
aspect of procurement controlling? One shouldn’t
be surprised, it`s whether one have one. This
question has a high difference coefficient of 75%. 
A little more than half of the companies within
all industries have on average a procurement
controlling. The most of the rest uses “some sort”
of a procurement controlling, like excel tools, which
have many times little or no acceptance outside of
the procurement department itself. Only 7% of the
companies say they use no procurement controlling
at all.
What about Pharmaceutical and Healthcare
companies? Only a third of these companies posses
a procurement controlling. More than 40% have
some procurement controlling tools, but more than
20% have no procurement controlling at all. That
way, Pharmaceutical and Healthcare companies
have more difficulties in measuring procurement
performance than other industries.
5.3 Procurement personnel and incentives 
For achieving ambitious procurement cost
reductions sufficient personnel resources and
appropriate qualification levels are needed. To
analyze the reasons for the given performance we
asked about number and capabilities of the
procurement resources. The study results show a
lack of sufficient qualified procurement personnel
Figure 5 Evaluation of qualification for procurement tasks for Chemical, Pharma, Healthcare and other industries.
Sufficient Rather
sufficient
Rather
insufficient
Insufficient
Chemical, Pharma, Healthcare
Other Industries
27% 26%
40%
57%
20%
15% 13%
2%
Σ 33%
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As our study reveals especially tendering seems to
be more relevant for companies in the Chemical,
Pharmaceutical and Healthcare industry than for
companies in other industries. The search for
potential new suppliers is given a distinctly minor
importance in Chemical, Pharmaceutical and
Healthcare industry. 
6.2 Time-dominant procurement topics in the
industry
For day-to-day operations the procurement
department of most companies is well positioned.
The analysis of the major time spending activities
in the procurement departments indicates that
procurement is associated as the place to carry out
orders and ensure supply stability. 
But in strategic functions of procurement there
is a totally different situation. Only half of the
working time which was evaluated as optimal for
strategic tasks, is available for these in procurement.
Tendering has a higher priority than in other
industries. The associated broad qualified search
for new suppliers gets also very little time in daily
operations.
These arguments lead to the results that
tendering is a (standardized) tool but it is not used
as broad and cost-effective as possible. It is
underpinned by a further analysis which indicates
procurement departments do rarely and little
tendering, in consideration of the total procurement
volume with less participating companies and above
all too few potential new suppliers – see figure 6. 
One of the most important levers for cost
function for their company. 
In many other industries this problem is a little
different, but bad as well. Many times companies
from these industries have experienced CPOs who
are experts in their area and understand the huge
cost reduction and value creating potential of
procurement. But this perception is not shared from
the other functions.
This induces pressure on motivation and a very
strong focus (sometimes over focus) on supply
reliability and an under focus on hands on cost
reduction. The lack of available and qualified
personnel is further intensified by the lack or
insufficient incentives of procurement personnel.
As study shows managers and staff in procurement
benefit too little and too rarely from achieved cost
savings – only 44% of the managers, well-fifth less
than in other industries and only 29% of employees
benefit from savings achieved. 
6. Processes
6.1 Major procurement topics in the industry
In general procurement in the Chemical,
Pharmaceutical and Healthcare industry has a
strong operational focus. Highest prioritized topics
are analysis of prices and offers, calculation and
planning of demand and management of supply
shortages. In comparison to the other industries in
the study, each of these topics has a relevance above-
average. 
The major topics in strategic procurement are
evaluation of suppliers, tendering and qualification
of suppliers as well as searching for new suppliers.
Figure 6 Assessment of the tender process in Chemical, Pharmaceutical and Healthcare and other industries.
Tender frequency Number of participating
suppliers
Number of new suppliers in
tender
Ø = 2,3 years Ø = 4 years Ø = 2 years
17%
42% 42%
38%
46%
8% 8%
19%
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6% 6%
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0%
2-3 3-5 5-10 10-20
0%
>20 <1 1-3 3-5 >5
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in the study state that they are not able to evaluate
their procurement performance compared to
competitors. This fraction was unbelievable 86% for
the Chemical, Pharmaceutical and Healthcare
industry compared to 56% in all other industries.
According to the perception about their
procurement performance 53% within the Chemical,
Pharmaceutical and Healthcare industry hold the
opinion that their procurement performance is above
average, only 13% say that their performance is below.
About this perception there is only a little difference
to companies from other industries, where 54% of
the participants say that their performance is above
average and only 10% declare that is below average.
Although the overconfidence bias seems to be
as high in Chemical, Pharmaceutical and Healthcare
as in the other areas because of similar numbers,
you have to take into account that on average
Chemical, Pharmaceutical and Healthcare companies
have a poor procurement performance according
to our measurement (Figure 2). So companies from
these industries face a bias higher than the average
bias. This bias inhibits necessary changes for a
realization of existing potentials.
A further examination about the bias shows that
the bias increases dramatically with lower
performance. Only the best quartile has no
overconfidence. But the worser the performance
gets the larger the bias – see figure 7.
The evaluation of this bias was created by a
comparison of self-perceived procurement
performance of companies and our measurement
of the company`s procurement performance.
reduction in procurement, a regular and broad
tendering is used insufficiently. As a result there
are unnecessary high procurement costs. As
mentioned before companies in Chemical,
Pharmaceutical and Healthcare industry show the
highest additional cost reduction potential due to
the financial crisis with 5.5% and fail to utilize 3.8%
- see figure 1.
The average tendering frequency in the
Chemical, Pharmaceutical and Healthcare industry
is 2.3 years (see Figure 6). This frequency is lower
compared to the average in all other industries with
a frequency of 1.9 years. The average participation
in the Chemical, Pharmaceutical and Healthcare
industry is four suppliers in a tender. This is a lower
average participant rate than in other industries
with on average six suppliers in a tender. Companies
in the Chemical, Pharmaceutical and Healthcare
industry have also a lower participant rate of new
suppliers in a tender by one compared to other
industries with on average three new suppliers in
a tender.
Therefore enormous cost reduction potentials
are left unexploited. In nearly every fifth company
is no potentially new supplier included – what
makes the tendering no longer a tendering as such.
This leads to a situation in which savings potential
is above average, which is especially true for indirect
procurement.
7. Mindset and bias in procurement
A lot of companies are not able to evaluate their
own procurement performance. This inability results
in a great bias of overconfidence. Most participants
Figure 7 Analysis of bias of self-perception according to performance quartile.
Quartile 1
Quartile 2
Quartile 3
Quartile 4
Too negative
self-perception
Unbiased self-
perception
Too positive
self-perception 
14%
10%
0%
0%
86%
59%
53%
21%
0%
32%
47%
79%
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visible. 
For further researches it might be interesting
to identify the mind set and personnel perceptions
of good and best-performing Chief Procurement
Officers (CPOs) as well as the appropriate mixture
of skills in procurement. It seems to be that
leadership skills and a low risk aversion are
important factors for high procurement
performance. 
8. Conclusion
While procurement in many industries achieved
first major successes by the development from a
simple buyer into a value-adding player between
the internal and external operations over the past
two decades, this process is neglected in Chemical,
Pharmaceutical, Healthcare industry, due to the
lower purchasing cost share and the excessive-
focus on security of supply. Through the comparison
to other industries significant gaps have been
identified in the areas of procurement strategy,
organizational model and daily business processes
as well as in realizing potentials.
The following actions should result in a reliable
higher performance and an improved standing of
procurement within the company:
1. Companies should look at procurement in a
more strategic way and set up a specific
procurement strategy that is clearly defined,
communicated and effectively applied. Hence
the alignment of the group strategy and
procurement strategy is paramount to act
accordingly. 
2. To use the momentum of changes it could be
beneficial to re-think the organizational line up
to make procurement become more efficient,
e.g. change the reporting line and responsibility
to the Chief Financial Officer (CFO) or to the
Chief Executive Officer (CEO) to drive the financial
performance or to transform the procurement
function from a pure service function to a more
strategic player in a company.
3. The procurement cost reduction potential has
not been fully exploited by most companies yet.
But as our study proves and best-practices show,
a change is not connected to high efforts. To
exploit saving potentials timely and quickly a
specific and approved procurement controlling
is needed. And it should be aligned with the
incentive system for procurement manager and
procurement personnel, to make the
performance visible and make them reliable. 
4. A more operative aspect is to increase the
participant ratio in tenders and ensure to look
at potential new suppliers. This will provide the
opportunity for significant cost reductions
5. Furthermore it is important to break out of the
biased and the too self-focused situation.
Companies should conduct regularly
benchmarks and communicate the results to
change or act accordingly, and make the progress
